Scientific Director at Nightingale Health; metabolic biomarker profiling for medical research and disease prevention
Jul 28, 2020 • 9 tweets • 5 min read
Coronary artery disease and lower extremity artery disease represent atherosclerosis in different vascular beds. We compared blood biomarker signatures for these 2 types of CVD: new preprint medrxiv.org/content/10.110…
based on @NgaleHealth metabolomics in @THLBiopankki Thread 👇
Peripheral artery disease (PAD) is understudied, and biomarkers analyses are commonly limited to classical risk factors. We used @NgaleHealth NMR metabolomics to study lipids and polar metabolites with the risk for future PAD events in 5 prospective Finnish cohorts (n=31,657).
Jul 6, 2020 • 38 tweets • 14 min read
How can we personalize protection of COVID-19 risk groups beyond age and existing conditions? New @NgaleHealth study identifies a blood biomarker score predicting risk of severe COVID-19, before contracting the virus medrxiv.org/content/10.110…#safereturntowork
We measured blood biomarkers by @NgaleHealth metabolomics in >100,000 samples from @uk_biobank. Blood samples were collected 10 years ago, metabolomics data became available late-May. This initiative will lead to many papers - we started with COVID-19. Summary on what we found 👇
